Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers

Joint Bone Spine

Volumn 84, Issue 2, 2017, Pages 133-140

  de La Forest Divonne, Maïté ^a,b   Gottenberg, Jacques Eric ^c,d   Salliot, Carine ^a,b  

^a Orleans Regional Hospital   (France)

^b UNIVERSITÉ D'ORLÉANS   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Biotherapies; Meta analyses; Registers; Rheumatoid arthritis; Safety

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

CARDIOVASCULAR DISEASE; DRUG EFFECT; DRUG SAFETY; HUMAN; INFECTION; LYMPHOMA; MALIGNANT NEOPLASM; MELANOMA; META ANALYSIS; MORTALITY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SYSTEMATIC REVIEW; PATIENT SAFETY; REGISTER;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; HUMANS; PATIENT SAFETY; REGISTRIES;

EID: 84995802148     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2016.02.028     Document Type: Short Survey

References (60)

1. [1] Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews and meta analyses: the PRISMA statement. J Clin Epidemiol 62 (2009), 1006–1012.
2. [2] de la Vega, M., da Silveira de Carvalho, H.M., Ventura Ríos, L., et al. The importance of rheumatology biologic registries in Latin America. Rheumatol Int 33 (2013), 827–835.
3. [3] Arora, A., Mahajan, A., Spurden, D., et al. Long-term drug survival of TNF inhibitor therapy in ra patients: a systematic review of European National Drug Registers. Int J Rheumatol, 2013, 30.
4. [4] van Vollenhoven, R.F., Askling, J., Rheumatoid arthritis registries in Sweden. Clin Exp Rheumatol 23 (2005), S195–S200.
5. [5] Mariette, X., Gottenberg, J.E., Ravaud, P., et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 50 (2011), 222–229.
6. [6] Hjardem, E., Hetland, M.L., Østergaard, M., et al. Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent. Ann Rheum Dis 64 (2005), 1220–1223.
7. [7] Ruderman, E.M., Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford) 51 (2012), vi37–vi43.
8. [8] Strangfeld, A., Hyrich, K., Askling, J., et al. Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. Rheumatology (Oxford) 50 (2011), 146–151.
9. [9] Pease, C., Pope, J.E., Truong, D., et al. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. Semin Arthritis Rheum 41 (2011), 81–89.
10. [10] Pease, C., Pope, J.E., Thorne, C., et al. Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial. J Rheumatol 37 (2010), 2469–2474.
11. [11] Curtis, J.R., Jain, A., Askling, J., et al. A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis registries. Semin Arthritis Rheum 40 (2010), 2–14.
12. [12] Cho, S.K., Sakai, R., Nanki, T., et al. A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan. Mod Rheumatol 24 (2014), 572–579.
13. [13] Greenberg, J.D., Furer, V., Farkouh, M.E., Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol 8 (2012), 13–21.
14. [14] Che, H., Lukas, C., Morel, J., et al. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine 81 (2014), 215–221.
15. [15] Ramiro, S., Gaujoux-Viala, C., Nam, J.L., et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73 (2014), 529–535.
16. [16] Le Blay, P., Mouterde, G., Barnetche, T., et al. Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. Clin Exp Rheumatol 30 (2012), 756–764.
17. [17] Kearsley-Fleet, L., Závada, J., Hetland, M.L., et al. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatol (Oxford) 54 (2015), 1074–1079.
18. [18] Carmona, L., Descalzo, M.A., Perez-Pampin, E., et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66 (2007), 880–885.
19. [19] Greenberg, J.D., Kremer, J.M., Curtis, J.R., et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 70 (2011), 576–582.
20. [20] Listing, J., Kekow, J., Manger, B., et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 74 (2013), 415–421.
21. [21] Lunt, M., Watson, K.D., Dixon, W.G., et al. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 62 (2010), 3145–3153.
22. [22] Morgan, C.L., Emery, P., Porter, D., et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology 53 (2014), 186–194.
23. [23] Dixon, W.G., Watson, K.D., Lunt, M., et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56 (2007), 2905–2912.
24. [24] Gibofsky, A., Palmer, W.R., Keystone, E.C., et al. Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries. J Rheumatol 38 (2011), 21–28.
25. [25] Listing, J., Strangfeld, A., Kekow, J., et al. Does tumor necrosis factor α inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. Arthritis Rheum 58 (2008), 667–677.
26. [26] Jung, L., Simard, J.F., Jacobsson, L., et al. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum 64 (2012), 42–52.
27. [27] Dixon, W.G., Watson, K.D., Lunt, M., et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for rheumatology biologics register. Arthritis Care Res 62 (2010), 755–763.
28. [28] Mercer, L.K., Low, A.S.L., Galloway, J.B., et al. Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. Ann Rheum Dis 72 (2013), 143–144.
29. [29] Strangfeld, A., Hierse, F., Rau, R., et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther, 12, 2010, R5.
30. [30] Carmona, L., Abasolo, L., Descalzo, M.A., et al. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum 41 (2011), 71–80.
31. [31] Dreyer, L., Mellemkjaer, L., Andersen, A.R., et al. Incidences of overall and site specific cancers in TNF inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry. Ann Rheum Dis 72 (2013), 79–82.
32. [32] Mercer, L.K., Green, A.C., Galloway, J.B., et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 71 (2012), 869–874.
33. [33] Mercer, L.K., Lunt, M., Low, A.L., et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum 74 (2015), 1087–1093.
34. [34] Raaschou, P., Simard, J.F., Neovius, M., et al. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 63 (2011), 1812–1822.
35. [35] Solomon, D.H., Kremer, J.M., Fisher, M., et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 43 (2014), 489–497.
36. [36] Askling, J., Baecklund, E., Granath, F., et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68 (2009), 648–653.
37. [37] Geborek, P., Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64 (2005), 699–703.
38. [38] Wolfe, F., Michaud, K., Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50 (2004), 1740–1751.
39. [39] Raaschou, P., Simard, J.F., Holmqvist, M., et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ, 346, 2013, f1939.
40. [40] Atzeni, F., Sarzi-Puttini, P., Botsios, C., et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 12 (2012), 225–229.
41. [41] Favalli, E.G., Desiati, F., Atzeni, F., et al. Serious infections during anti-TNFα treatment in rheumatoid arthritis patients. Autoimmun Rev 8 (2009), 266–273.
42. [42] Galloway, J.B., Hyrich, K.L., Mercer, L.K., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 50 (2011), 124–131.
43. [43] Van Dartel, S.A.A., Fransen, J., Kievit, W., et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 72 (2013), 895–900.
44. [44] Komano, Y., Tanaka, M., Nanki, T., et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the registry of Japanese rheumatoid arthritis patients for longterm safety. J Rheumatol 38 (2011), 1258–1264.
45. [45] Listing, J., Strangfeld, A., Kary, S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52 (2005), 3403–3412.
46. [46] Simard, J.F., Arkema, E.V., Sundström, A., et al. Ten years with biologics: to whom do data on effectiveness and safety apply?. Rheumatol (Oxford) 50 (2011), 204–213.
47. [47] Barnabe, C., Martin, B.-J., Ghali, W.A., Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 63 (2011), 522–529.
48. [48] Mariette, X., Tubach, F., Bagheri, H., et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 69 (2010), 400–408.
49. [49] Brown, S.L., Greene, M.H., Gershon, S.K., et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46 (2002), 3151–3158.
50. [50] Keane, J., Gershon, S., Wise, R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001), 1098–1104.
51. [51] Askling, J., Fored, C.M., Brandt, L., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66 (2007), 1339–1344.
52. [52] Dixon, W.G., Watson, K., Lunt, M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006), 2368–2376.
53. [53] Tubach, F., Salmon, D., Ravaud, P., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60 (2009), 1884–1894.
54. [54] Salmon-Ceron, D., Tubach, F., Lortholary, O., et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 70 (2011), 616–623.
55. [55] Strangfeld, A., Listing, J., Herzer, P., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301 (2009), 737–744.
56. [56] Cobo-Ibáñez, T., Descalzo MÁ, Loza-Santamaría, E., et al. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatol Int 34 (2014), 953–961.
57. [57] Weaver, A., Troum, O., Hooper, M., et al. Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in RADIUS 1. J Rheumatol 40 (2013), 1275–1281.
58. [58] Gottenberg, J.E., Ravaud, P., Bardin, T., et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62 (2010), 2625–2632.
59. [59] Salmon, J.H., Gottenberg, J.E., Ravaud, P., et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis 75 (2016), 1108–1113 [pii: annrheumdis-2015-207362].
60. [60] Roubille, C., Richer, V., Starnino, T., et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74 (2015), 480–489.